Skip to main content

Lantern Pharma, NCI Collaborate to ID Gene Signatures Predictive of Cancer Treatment

NEW YORK – Lantern Pharma announced it will work with the National Cancer Institute's developmental therapeutics branch to identify and validate gene signatures that predict whether patients are likely to respond to treatments it is developing.

Within the collaboration, Lantern will use its CellMiner and CellMinerCDB artificial intelligence platforms, and apply regression models and algorithms to categorize genetic markers that predict response or confer sensitivity to drug candidates within its therapeutic pipeline. In the process, Lantern will be able to draw on NCI-generated omics datasets on DNA mutations, mRNA or miRNA expression, DNA methylation, DNA copy number, and protein arrays, which will provide greater insights into the mechanism of action of the investigational drugs it is developing.

"Lantern believes that the convergence of artificial intelligence, machine learning, and genomic data mark the next frontier for a highly productive period in drug development, especially in cancer therapeutics," Lantern CEO Panna Sharma said in a statement.

The oncology-focused biotech aims to create a curated list of multi-omics signatures predictive of drug efficacy and validate them. Lantern further said it will work with the NCI to publish the results that comes out of the collaboration.